Weihong Hsing, Ph.D., is a partner in the Intellectual Property Group of Ice Miller. She counsels clients, ranging from Fortune 50 to start-up companies, on domestic and worldwide patent portfolio development and management, providing strategic advice on IP protection throughout the product lifecycle in areas such as biotechnology, pharmaceuticals, agriculture and diagnostics. She also has extensive experience in IP due diligence, conducting IP portfolio evaluations and freedom to operate analysis in connection with mergers & acquisitions and investments. Her practice further includes opinion work on patent validity and infringement, post-issuance proceedings and licensing, as well as technical support for patent litigation.
With a Ph.D. in microbiology, postdoctoral training in molecular biology and genetics and years of research experience in academic and industrial settings, Weihong enjoys learning about the latest ideas from her practice and remaining close to the research world. She is able to assist clients with their patent needs in many technical fields, encompassing immunotherapies, CAR-T, gene therapies, vaccines, dermatology, small molecule therapeutics, antibody-drug conjugates, biomarkers, diagnostics, herbicides, improved formulations, transgenic plants and animals, recombinant cells, CRISPR, novel platforms and assays, etc.
Weihong started her patent career as a patent manager at Johnson & Johnson, where she drafted and prosecuted patent applications, undertook clearance search and analysis and assisted with strategic counseling and patent portfolio development and management. Prior to joining Ice Miller, Weihong was a partner at an IP boutique, heading the life sciences practice of that firm.
Prior to her legal career, Weihong was a research scientist at Princeton University and a senior scientist at a biotech start-up company. She is an inventor of several biotech inventions and an author of publications in leading scientific journals such as Science and Nature.
News
Published In
- Hsing, W., 2012, “Guaranteeing IP protection when working with overseas partners,” Chimica Oggi-Chemistry Today, CROs/CMOs & Related Services, 30(4): 31-34.
- Hsing, W., 2012, “Patent Protection on Personalized Medicine In view of Mayo v. Prometheus,” SAPA-GP 10th Anniversary Issue, p38-40.
- Mihalcescu I., W. Hsing, S. Leibler, 2004, “Resilient circadian oscillator revealed in individual cyanobacteria,” Nature, 430: 81-85.
- Guet C., M. Elowitz, W. Hsing, S. Leibler, 2002, “Combinatorial synthesis of genetic networks,” Science, 296:1466-1470.
- Menzel, R., W Hsing and Taggart P, US 6265174, 2001, Methods and Compositions for identifying and modulating ctionprotein-interactions
- Hsing, W., F. D. Russo, K. K. Bernd, and T. J. Silhavy, 1998, “Mutations that alter the kinase and phosphatase activities of the two-component sensor, EnvZ,” J. Bacteriol. 180: 4538-4546.
- Hsing, W., and T. J. Silhavy, 1997, “The function of the conserved His-243 for the phosphatase activity of EnvZ, the sensor for porin osmoregulation in Escherichia coli,” J. Bacteriol. 179: 3729-3735.
- Hsing, W., and E. Canale-Parola, 1996, “A methyl-accepting chemotaxis protein involved in multiple-sugar chemotaxis by Cellulomonas gelida,” J. Bacteriol. 178:5153-5158.
- Pratt, L. A., W. Hsing, K. E. Gibson and T. J. Silhavy, 1996, “From acids to osmZ: multiple factors influence synthesis of OmpF and OmpC porins in Escherichia coli,” Molecular Microbiology 20(5):911-917.
- Hsing, W., and E. Canale-Parola, 1992, “Cellobiose chemotaxis by the cellulolytic bacterium Cellulomonas gelida,” J. Bacteriol. 174:7996-8002.